Revisiting serum beta-human chorionic gonadotropin concentrations as a predictor for dizygotic twinning after in vitro fertilization


OLGAN Ş., Bozdag G., Sokmensuer L., Mumusoglu S., GÜNALP G. S.

Clinical and Experimental Obstetrics and Gynecology, cilt.43, sa.4, ss.597-601, 2016 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 43 Sayı: 4
  • Basım Tarihi: 2016
  • Doi Numarası: 10.12891/ceoj.3525.2016
  • Dergi Adı: Clinical and Experimental Obstetrics and Gynecology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.597-601
  • Anahtar Kelimeler: Beta-human chorionic gonadotropin, Dizygotic twinning, Double embryo transfer, In vitro fertilization
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

Purpose of investigation: To determine a cut-off value for beta-human chorionic gonadotropin (P-hCG) concentrations to predict dizygotic twinning after in vitro fertilization (IVF) and double embryo transfer (DET). Materials and Methods: This retrospective cohort study included 233 women who conceived after DET at IVF center, Hacettepe University Faculty of Medicine. Patients with serum P-hCG concentration > 25 1U/1 assayed on day 14 after oocyte retrieval were included into the study. Results: Lower serum 0-hCG concentrations were observed in non-viable pregnancy when compared to their viable counterparts. In addition, twins exhibited higher p-hCG concentrations than singletons did. Receiver operator characteristic (ROC) curve analysis showed a significant relationship between serum p-hCG concentrations and the occurrence of twin pregnancy (area under the curve = 0.85,95% confidence interval = 0.79-0.91, p < 0.001). For twin pregnancy, when P-hCG > 175 1U/1, sensitivity was 77.3%, specificity was 80.0%, positive predictive value (PPV) was 48.2%, and negative predictive value (NPV) was 93.8%. Conclusion: P-hCG > 175 1U/1 might be used as a new cut-off value for early prediction of viable dizygotic twins following IVF-DET treatment cycles.